Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Switch Maintenance Study

ABSTRACT: Interventions: CapeOX+Bev ;Capecitabine1000mg/m2 oral administration twice a day Day1-15+Oxaliplatin130mg/m2 120minute DIV+Bevacizumab5.0 mg/kg given on day 1,15 FOLFOX+Bev;Oxaliplatin85mg/m2 120minute DIV+LEVOFOLINATE200mg/m2 120minute DIV+Fluorouracil400mg/m2 rapid DIV+Fluorouracil2400mg/m2 46minute DIV+Bevacizumab DIV5.0 mg/kg Day1,15 TAS-102+Bev;TAS-102 35 mg/m2/time,oral administration twice a day Day1-5, TAS-102 oral administration twice a day Day8-12+Bevacizumab DIV5.0 mg/kg Day1,15 Primary outcome(s): Progression free survival Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Colorectal Cancer

PROVIDER: 2612965 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer

Project description:Interventions: TAS-102 plus Bevacizumab TAS-102 35 mg/time, twice a day, oral intake Day1-5,8-12 Bevacizumab venous injection, 5.0 mg/kg Day1,15 Patients will continue study treatment until disease progression Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2646473 | ecrin-mdr-crc

JCOG1018: Rp3 Study in Elderly Patients with MEtastatic CRC as 1st-line Tx

Project description:Interventions: Arm A: 5-FU/LV or CAP + BEV 1. 5-FU/l-LV (msDG) + BEV (1) BEV: 5 mg/kg, iv, day 1 (2) l-LV: 200 mg/m2, iv, day 1 (3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3 2. CAP + BEV [ 50 mL/min <= Ccr ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) CAP: 1,250 mg/m2, oral, twice a day, day 1-14 [ 30 mL/min <= Ccr<50 mL/min ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) CAP: 1,000 mg/m2, oral, twice a day, day 1-14 Arm B: 5-FU/LV or CAP + L-OHP + BEV 1. mFOLFOX7 + BEV (1) BEV: 5 mg/kg, iv, day 1 (2) l-LV: 200 mg/m2 + L-OHP:85 mg/m2, iv, day 1 (3) 5-FU: 2,400 mg/m2/46 hr, civ, day 1-3 2. CAPOX + BEV [ 50 mL/min <= Ccr ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) l-LV: 130 mg/m2, iv, day 1 (3) CAP: 1,000 mg/m2,oral, twice a day, day, day 1-14 [ 30 mL/min <= Ccr < 50 mL/min ] (1) BEV: 7.5 mg/kg, iv, day 1 (2) L-OHP: 130 mg/m2, iv, day 1 (3) CAP: 750 mg/m2, oral, twice a day, day 1-14 Primary outcome(s): Progression-free survival Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2614012 | ecrin-mdr-crc

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody

Project description:Interventions: Level1 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 24 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div. day1,8 U3-1565: 16 mg/kg div day1 q2w Level0 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 16 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div day1,8 U3-1565: 12 mg/kg div day1,8 q2w Primary outcome(s): Proportion of DLT(Dose limiting toxicity) Study Design: Single arm Non-randomized

| 2628359 | ecrin-mdr-crc

JCOG2014: Randomized phase III study of bi-weekly trifluridine/tipiracil plus bevacizumab vs trifluridine/tipiracil alone for chemorefractory metastatic colorectal cancer

Project description:Interventions: A: FTD/TPI monotherapy FTD/TPI (35 mg/m2 given orally twice daily on days 1-5 and 8-12 in a 28-day cycle) B: Bi-weekly FTD/TPI+BEV combination Bi-weekly FTD/TPI (35 mg/m2 given orally twice daily on days 1-5 in a 14-day cycle) with BEV (5 mg/kg on day1, every 2 weeks) Primary outcome(s): Overall survival Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2614546 | ecrin-mdr-crc

A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin

Project description:Interventions: TAS-102 25-35 (mg/m2) day1-5 CPT-11 150-180 (mg/m2) day 1 Bevacizumab 5 (mg/kg) day 1 every 2 weeks Primary outcome(s): Part1(dose-escalation): DLT between first 2 cycles Part2(expansion): the incidence of febrile neutropenia Study Design: Single arm Non-randomized

| 2635113 | ecrin-mdr-crc

Phase II study of TAS-102 in patients with metastatic colorectal cancer

Project description:Intervention name : TAS-102 Dosage And administration of the intervention : TAS-102 70 mg/m2 was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. Control intervention name : Placebo Dosage And administration of the control intervention : Placebo was administered orally twice a day for 5 days followed by 2 day rest and repeated two times this procedure. Primary outcome(s): Overall survival To evaluate the overall survivals of TAS-102 versus placebo in patients with chemotherapy-refractory metastatic colorectal cancer Study Design: Randomized, double-blind, placebo-controlled, parallel-group comparative study

| 2610203 | ecrin-mdr-crc

TAS-102 and Bevacizumab as third line chemotherapy for colorectal cancer. Phase 2 trial

Project description:Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle. Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2645202 | ecrin-mdr-crc

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed R6/2 mice.

Project description:R6/2 and WT mice treated orally twice a day with vehicle (10% HPβCD), and R6/2 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 - 12 weeks of age.

2017-09-23 | GSE104086 | GEO

RNAseq data on HDAC Class IIa inhibitor (CHDI-00390576) dosed Q175 mice.

Project description:WT and Q175 heterozygous (het) mice treated orally twice a day with vehicle (10% HPβCD), and Q175 mice treated with either 30 or 100 mg/kg orally twice a day CHDI-00390576. CHDI-00390576 is a Class IIa HDAC inhibitor. Mice were dosed from 4 weeks to 6 months of age.

2017-09-23 | GSE104064 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data